Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.

Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.

Dapson (Dapsone, 4,4′-Diaminodiphenyl sulfone, 4,4′-Sulfonyldianiline, 4-Aminophenyl sulfone, Bis(4-aminophenyl) sulfone, DDS), also known as diaminodiphenyl sulfone (DDS), is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy.

Dapson (Dapsone, 4,4′-Diaminodiphenyl sulfone, 4,4′-Sulfonyldianiline, 4-Aminophenyl sulfone, Bis(4-aminophenyl) sulfone, DDS), also known as diaminodiphenyl sulfone (DDS), is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy.

DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.

DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.

Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.

Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.

Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.

Darapladib is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM. Phase 3.

Darapladib is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM. Phase 3.

Darapladib is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM. Phase 3.

Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

Darifenacin HBr (UK-88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9.

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with Ki of 11 nM. Phase 3.

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with Ki of 11 nM. Phase 3.

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with Ki of 11 nM. Phase 3.

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with Ki of 11 nM. Phase 3.

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Darunavir (TMC114,DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.

Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.

Darutigenol has antithrombotic effect and may be related to inhibition of platelet aggregation and adhesion.

Darutoside, derived from botanical extracts, has a powerful regenerating action via decreasing inflammation and restoring collagen.

Darutoside, derived from botanical extracts, has a powerful regenerating action via decreasing inflammation and restoring collagen.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of